DEFA14A: Lucid Diagnostics Reschedules Annual Stockholders Meeting to July 23, 2024, Due to Proposal Modifications

Lucid Diagnostics Inc. has rescheduled its 2024 annual meeting of stockholders from June 20, 2024, to July 23, 2024, to modify the proposals to be voted upon.

Summary

• Lucid Diagnostics Inc. has rescheduled its 2024 annual meeting of stockholders.
• The meeting was originally scheduled for June 20, 2024, at 11:00 a.m. Eastern Time.
• The new date for the Annual Meeting is July 23, 2024, at 11:00 a.m. Eastern Time.
• The rescheduling is due to modifications to the proposals to be voted upon at the meeting.
• A new record date of May 29, 2024, has been established to determine stockholders entitled to notice and to vote.
• The company will send a new notice and proxy statement for the rescheduled meeting.
• The location of the Annual Meeting remains unchanged, and stockholders can participate online.
• The company is filing a revised preliminary proxy statement with the SEC and will mail a revised definitive proxy statement and proxy card to stockholders.
• Investors and security holders are encouraged to read the revised proxy statements and other relevant documents filed with the SEC.
• The company and its directors and executive officers may be deemed participants in the solicitation of proxies.

Sentiment

Score: 5

Explanation: The announcement is neutral, simply stating a change in the date of the annual meeting due to modifications in proposals.

Future Outlook

The company will file and distribute revised proxy materials to stockholders in advance of the rescheduled annual meeting.

Industry Context

This announcement is a routine procedural update related to corporate governance and shareholder engagement, which is common for publicly traded companies.

Stakeholder Impact

• Shareholders need to be aware of the new meeting date and record date.
• Shareholders should review the revised proxy materials when available to make informed voting decisions.

Next Steps

• The Company will send a new notice and proxy statement for the rescheduled Annual Meeting.
• The Company will file a revised preliminary proxy statement on Schedule 14A with the Securities and Exchange Commission (the SEC).
• The Company will mail the revised definitive proxy statement and a revised proxy card to each stockholder entitled to vote at the rescheduled Annual Meeting.

Key Dates

Keywords

Annual Meeting, Lucid Diagnostics, Stockholders, Proxy Statement, Reschedule, SEC, Voting